Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-04-01-01 Raloxifene
| Raloxifene Hydrochloride Evista® |
|
Formulary
|
Tablets 60mg |
 NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women NICE TA161:Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
|
Secondary prevention of osteoporosis (NICE TA161)
Primary prevention of osteoporosis in postmenopausal women - not recommended by NICE TA160 updatedLinks
- BMS: BMS statement in response to the publication of the updated NICE Menopause guideline (NG23)
- LSCMMG: Estradiol / micronised progesterone
LSCMMG: Trans Female Gender Dysphoria Information Sheet- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
- NICE NG23: Menopause: identification and management
- NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE TA161:Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women